Gerhard Siemeister

PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.

J M Wood, Guido Bold, Elisabeth Buchdunger et al. · PubMed · 2000 · 847 citations

Medicine, Oncology, Pharmacology +16

Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS–SOS1 interaction

R.C. Hillig, Brice Sautier, Jens Schroeder et al. · Proceedings of the National Academy of Sciences · 2019 · 379 citations · Full text

Medicine, Molecular Biology, Oncology +17

Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein.

Gerhard Siemeister, Karin Weindel, Katja Mohrs et al. · PubMed · 1996 · 310 citations

Medicine, Genetics, Oncology +17

Vascular endothelial growth factor up-regulates its receptor fms-like tyrosine kinase 1 (FLT-1) and a soluble variant of FLT-1 in human vascular endothelial cells.

Bernhard Barleon, Gerhard Siemeister, Georg Martiny‐Baron et al. · PubMed · 1997 · 218 citations

Medicine, Cancer Biology, Oncology +16

The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models

Antje M. Wengner, Gerhard Siemeister, Ulrich Lücking et al. · Molecular Cancer Therapeutics · 2019 · 210 citations

Medicine, Molecular Biology, Oncology +17